Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant  Ahmad Hatem Mattour,

Slides:



Advertisements
Similar presentations
Emberger Syndrome with Concomitant GATA2, NPM1 and FLT3-ITD Mutations in Remission after Allogeneic Stem Cell Transplant  Abhijit Balkrishna Saste, MD,
Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.
Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,
Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Gunjan L. Shah,
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.
Biology of Blood and Marrow Transplantation
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.
Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Biology of Blood and Marrow Transplantation
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.
Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection  Ron Mihelic,
Biology of Blood and Marrow Transplantation
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
Cytomegalovirus Reactivation Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Chemotherapeutics.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients  LeAnne Kennedy, Marie Cavalier,
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma  Christopher Parrish, Amin Rahemtulla, Jim.
Incidence of Post-Transplant Bacterial Foodborne Pathogens in Hematopoietic Stem Cell Transplant Patients  Nicole Boyle, Sara Podczervinski, Kim Jordan,
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation  Koji Sasaki, MD, Rima Saliba, PhD, Gary.
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma  Dharshan Sivaraj, Michael.
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.
Hayder Saeed, MD, Michael C
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation  Mohammed M. Elayan, Justin G.
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival  Victor H. Jimenez-Zepeda,
What is quality in a transplant program?
Outcomes of Salvage Second Autologous Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma in the Era of Modern Therapy  Emily Case Ayers,
Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Blood and Marrow Transplant Handbook
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Mark A. Fiala, Joseph D. Finney, Keith.
A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome  Peggy A. Wu,
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Treatment versus Transplant for Challenging Hematologic Disorders
Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation 
Mary Eapen  Biology of Blood and Marrow Transplantation 
In Memoriam: E. Donnall Thomas
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Luciano J. Costa, Jia-Xing Huang, Parameswaran.
Cerebral Venous Thrombosis after Autologous Stem Cell Transplantation
Presentation transcript:

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant  Ahmad Hatem Mattour, MD, Nalini Janakiraman, M.D., Shatha Farhan, M.D., Edward Peres, M.D.  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, (February 2015) DOI: 10.1016/j.bbmt.2014.11.198 Copyright © 2015 Terms and Conditions

Figure 1 Biology of Blood and Marrow Transplantation 2015 21, DOI: (10.1016/j.bbmt.2014.11.198) Copyright © 2015 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.